Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer (POWER)

Clinical Trial ID NCT01627379

Rank	Title	Journal	Year	PubWeight™‹?›
1	Platinum-based chemotherapy plus cetuximab in head and neck cancer.	N Engl J Med	2008	11.86
2	Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.	Lancet	2002	8.46
3	Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.	Ann Oncol	2009	1.46
4	Advances in targeted therapies and new promising targets in esophageal cancer.	Oncotarget	2015	0.87
5	Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction.	Cochrane Database Syst Rev	2006	0.85
6	Personalized targeted therapy for esophageal squamous cell carcinoma.	World J Gastroenterol	2015	0.82
7	Targeted treatments for metastatic esophageal squamous cell cancer.	World J Gastrointest Oncol	2013	0.81
8	Combination of cetuximab with radio-chemotherapy in patients with esophageal cancer: less is more!	J Thorac Dis	2015	0.77
9	New and emerging combination therapies for esophageal cancer.	Cancer Manag Res	2013	0.77